NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NPSP) will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2012 at 10:30 a.m. PT. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors calendar of events page on the NPS website at http://www.npsp.com.
About NPS Pharmaceuticals
NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX® (teduglutide) in adult short bowel syndrome (SBS) and NATPARATM (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPS earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Source: NPS Pharmaceuticals, Inc.Copyright Business Wire 2012